LUND, Sweden, May 28, 2021
/PRNewswire/ -- Immunovia AB (publ) ("Immunovia") announces today
that Patrik Dahlen, CEO of
Immunovia, has purchased 6,860 shares for approximately
SEK 675,000 over the stock exchange.
His total holding now amounts to 51,860 shares in Immunovia.
Immunovia AB is a diagnostic company that is developing and
commercializing highly accurate blood tests for the early detection
of cancer and autoimmune diseases based on Immunovia's
proprietary test platform called IMMray™. Tests are based on
antibody biomarker microarray analysis using advanced
machine-learning and bioinformatics to single-out a set of relevant
biomarkers that indicate a certain disease. Thus, forming a unique
"disease biomarker signature".
The company was founded in 2007, based on cancer studies and
ground-breaking research in the Department of Immuntechnology at
Lund University and CREATE Health
Cancer Center, Sweden.
The first product, IMMray™ PanCan-d, is undergoing clinical
evaluation in some of the world's largest clinical studies for
pancreatic cancer, PanFAM-1, PanSYM-1 and PanDIA-1. The final
validation study was completed in Q1 2021. The accreditation
process forImmunovia Inc. in Marlborough, Massachusetts, USA is ongoing and commercial
testing will begin in Q2 after the accreditation. The European
launch plan will be communicated Q2 2021.
IMMray™ PanCan-d will be the first blood-based test for early
diagnosis of pancreatic cancer on the market, with a potential to
significantly improve patient survival and outcome. The test will
be exclusively provided by Immunovia Inc., Marlborough, Massachusetts, USA.
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For
more information, please visit www.immunovia.com.
For more information, please contact:
Patrik Dahlen, CEO Immunovia
Tel: +46 73 376 76 64
This information was brought to you by Cision
The following files are available for download:
SOURCE Immunovia AB